Trials / Completed
CompletedNCT02184351
Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis
A Prospective Randomized, Blinded Parallel Group Study of Clotrimazole Troches vs. Mycelex® Troches (10 mg Troche Five Times a Day for 14 Days) in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 187 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to compare the efficacy and safety of Roxane's clotrimazole troches vs. Mycelex troches in HIV positive patients with oropharyngeal candidiasis, where this condition has been diagnosed by clinical examination and confirmed by fungal culture.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Roxanes's clotrimazole troches | |
| DRUG | Mycelex® troches |
Timeline
- Start date
- 2001-05-01
- Primary completion
- 2001-11-01
- First posted
- 2014-07-09
- Last updated
- 2014-07-14
Source: ClinicalTrials.gov record NCT02184351. Inclusion in this directory is not an endorsement.